Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | CPS1 | P31327 | 2/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283993 | 0.88 | ALDH1A1 (0.52) | ALDH1A1ALOX15CSNK2A1CES2CES1 | |
| SCHEMBL302204 | 0.85 | CSNK2A1 (0.48) | CSNK2A1HDAC7MEN1KMT2ALMNA | |
| SCHEMBL9726681 | 0.83 | CSNK2A1 (0.47) | ALDH1A1CSNK2A1CES2CES1LOXL2 | |
| SCHEMBL1226712 | 0.81 | KMT2A (0.46) | ALDH1A1CSNK2A1CES2CES1LOXL2 | |
| SCHEMBL489010 | 0.81 | CSNK2A1 (0.61) | ALDH1A1CSNK2A1LOXL2MEN1KMT2A | |
| SCHEMBL29688899 | 0.81 | KMT2A (0.46) | ALDH1A1CSNK2A1CES2CES1LOXL2 | |
| SCHEMBL15255736 | 0.79 | CSNK2A1 (0.44) | CSNK2A1CES2CES1LOXL2CPS1 | |
| SCHEMBL1003133 | 0.79 | DGAT1 (0.60) | CSNK2A1CES2CES1LOXL2CPS1 | |
| SCHEMBL20560315 | 0.79 | LOXL2 (0.38) | CSNK2A1CES2CES1LOXL2CPS1 | |
| SCHEMBL18224251 | 0.79 | CSNK2A1 (0.59) | ALDH1A1CSNK2A1HDAC7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114507159-B | Preparation method of 4- [3 (E) -pentene-1-yl ] benzoate liquid crystal monomer | 中节能万润股份有限公司 | 2024-05-03 | — | — | CN | claimed |
| CN-114507159-A | Preparation method of 4- [3(E) -penten-1-yl ] benzoate liquid crystal monomer | 中节能万润股份有限公司 | 2022-05-17 | — | — | CN | claimed |
| CN-114929688-B | 3- (4- (11H-dibenzo [ b, e ] [1,4] azepin-6-yl) piperazin-1-yl) -and 3- (4- (dibenzo [ b, f ] [1,4] oxazepin/thiazepin/diazepin-11-yl) piperazin-1-yl) -propionic acid derivatives as H1 and 5-HT 2A-receptor modulators for the treatment of sleep disorders | 阿莱瑞恩公司 | 2024-11-01 | — | — | CN | disclosed |
| EP-4048667-B1 | 3-(4-(11H-DIBENZO[B,E][1,4]AZEPIN-6-YL)PIPERAZIN-1-YL)- AND 3-(4-(DIBENZO[B,F][1,4]OXAZEPIN/THIAZEPIN/DIAZEPIN-11-YL)PIPERAZIN-1-YL)-PROPANOIC ACID DERIVATIVES AS H1 AND 5-HT2A-RECEPTOR MODULATORS FOR THE TREATMENT OF SLEEP DISORDERS | ALAIRION INC (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-114507159-B | Preparation method of 4- [3 (E) -pentene-1-yl ] benzoate liquid crystal monomer | 中节能万润股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-4048667-A1 | 3-(4-(11H-DIBENZO[B,E][1,4]AZEPIN-6-YL)PIPERAZIN-1-YL)- AND 3-(4-(DIBENZO[B,F][1,4]OXAZEPIN/THIAZEPIN/DIAZEPIN-11-YL)PIPERAZIN-1-YL)-PROPANO IC ACID DERIVATIVES AS H1 AND 5-HT2A-RECEPTOR MODULATORS FOR THE TREATMENT OF SLEEP DISORDERS | Alairion, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| CN-114929688-A | 3- (4- (11H-dibenzo [ b, e ] [1,4] azepin-6-yl) piperazin-1-yl) -and 3- (4- (dibenzo [ b, f ] [1,4] oxazepin/thiazepin/diazepin-11-yl) piperazin-1-yl) -propionic acid derivatives as H1 and 5-HT 2A-receptor modulators for the treatment of sleep disorders | 阿莱瑞恩公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-114507159-A | Preparation method of 4- [3(E) -penten-1-yl ] benzoate liquid crystal monomer | 中节能万润股份有限公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-114380762-A | Isoxazoline hydrazide derivative and preparation method and application thereof | 贵州大学 | 2022-04-22 | — | — | CN | disclosed |
| US-11203571-B2 | Sulfonamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-21 | — | — | US | disclosed |
| US-11203571-B2 | Sulfonamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-21 | — | — | US | disclosed |
| US-7553850-B2 | Tricyclic-bridged piperidinylidene derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA NV (BG) | 2009-06-30 | — | — | US | disclosed |
| WO-2009074677-A2 | PYRAZOLOTRIAZINES | 4SC AG (DE) | 2009-06-18 | — | — | WO | disclosed |
| EP-2070932-A1 | Pyrazolotriazines | 4SC AG (DE) | 2009-06-17 | — | — | EP | disclosed |
| EP-2035426-A1 | PYRAZOLOPYRIMIDONES | 4SC AG (DE) | 2009-03-18 | — | — | EP | disclosed |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | disclosed |
| CN-101208302-A | Novel 4-aminopiperidine derivatives as plasmepsin ii inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2008-06-25 | — | — | CN | disclosed |
| WO-2007144384-A1 | PYRAZOLOPYRIMIDONES | 4SC AG (DE) | 2007-12-21 | — | — | WO | disclosed |
| US-4046905-A | Anti-inflammatory, analgesic and antipyretic phenylacetic acids | MERCK & CO., INC. (US) | 1977-09-06 | — | — | US | disclosed |
| US-3947582-A | Phenylacetic acid compounds in treating abnormal platelet aggregation | MERCK & CO., INC. (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11203571-B2 | Sulfonamides as modulators of sodium channels | TRPV1, SCN1A, SCN5A | ALDH1A1 1877/4885ALOX15 2276/4885CSNK2A1 821/4885 |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | ALDH1A1 1302/4885ALOX15 1604/4885CSNK2A1 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.